{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["8(4)"],"submitter":["Di M"],"pubmed_abstract":["High upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited. Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%). Our peri-CAR-T period of interest was from 41 days before to 154 days after CAR-T therapy index divided into seven 28-day intervals. Median total costs were $608 100 (interquartile range, IQR = $534 100-$732 800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402 500, and the median out-of-pocket copayment was $510"],"journal":["JNCI cancer spectrum"],"pagination":["pkae059"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11340641"],"repository":["biostudies-literature"],"pubmed_title":["Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas."],"pmcid":["PMC11340641"],"pubmed_authors":["Di M","Isufi I","Gross CP","Huntington SF","Seropian S","Foss F","Potnis KC","Long JB"],"additional_accession":[]},"is_claimable":false,"name":"Costs of care during chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell lymphomas.","description":"High upfront cost may be a barrier to adopting chimeric antigen receptor T-cell (CAR-T) therapy for relapsed or refractory B-cell lymphoma. Data on the real-world costs are limited. Using the Blue Cross Blue Shield Axis database, we evaluated 271 commercially insured patients who received CAR-T therapy for B-cell lymphoma (median age = 58 years; men = 68%; diffuse large B-cell lymphoma = 87%; inpatient CAR-T therapy = 85%). Our peri-CAR-T period of interest was from 41 days before to 154 days after CAR-T therapy index divided into seven 28-day intervals. Median total costs were $608 100 (interquartile range, IQR = $534 100-$732 800); 8.5% of patients had total costs exceeding $1 million. The median cost of CAR-T therapy products was $402 500, and the median out-of-pocket copayment was $510","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Jul","modification":"2025-04-18T13:09:42.145Z","creation":"2025-04-06T22:42:53.221Z"},"accession":"S-EPMC11340641","cross_references":{"pubmed":["39115391"],"doi":["10.1093/jncics/pkae059"]}}